Sensitive Choice-Certified Coway Airmega Offers Trusted Relief for Spring Allergy Season
Highlights Sensitive Choice certified Airmega 350 for open-plan living alongside 11-time Wirecutter winner Airmega Mighty Offers up to 44% off on Amazon Australia Prime Big Deal Days to support 2.8 million Australians living with respiratory conditions SYDNEY, Sept. 29, 2026 /PRNewswire/ -- Coway, South Korea's leading wellness tech company,...
iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. CHENGDU, China, Sept. 29, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, today announced that its investigational cell therapy NouvSight001 has received clearance from China's...
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) today announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and...
Natural Field to Showcase Liposomal Delivery Technology and Healthy Aging Nutrition Solutions at Hi Japan 2026
SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Natural Field, a global nutraceutical ingredient solutions provider, announced its participation in Hi Japan 2026, where the company will present its advanced liposomal delivery technologies and NF TriSolve® Healthy Aging Solutions at Booth 2-209. Hi Japan 2026 provides a professional platform connecting health ingredient suppliers,...
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-weekly oral dosing. - Placebo-adjusted reduction in PASI score reached 65.9% in mild-to-moderate...
Regent Pacific (0575.HK)’s Deep Longevity Launches Accrua™ US Consumer Digital Health and Telehealth Platform
Available Across All 50 US States, Extending Deep Longevity's AI-Powered Ageing Science Directly to Consumers for a Second Growth Curve HONG KONG, Sept. 28, 2026 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company", together with its subsidiaries, the "Group"; stock code: 0575.HK), is pleased to announce that Deep Longevity, its AI-powered biological ageing intelligence subsidiary, will...
Open-Source Model Accelerates Global Progress in Medical Video AI
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- Through an open-source model, a public dataset and benchmark, and the MedVidU Challenge, a global research competition, researchers worldwide now share a common foundation for advancing medical video AI. The Challenge drew 75 teams from 18 countries and regions across five continents, bringing diverse ideas and approaches into an ecosystem shaped by...
Lunit Expands AI-Powered Breast Cancer Screening Across the Stockholm Region
Following years of clinical validation and proven real-world performance at Saint Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent second reader at regional scale SEOUL, South Korea, Sept. 28, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that its...
Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million
– LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD Anderson Cancer Center – – Jie D'Elia, Ph.D., joins as Chief Executive Officer and Friedrich Graf Finckenstein, M.D., as Chief Medical Officer; co-founder Brian...
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that the China National Medical Products Administration (NMPA) has approved Jaypirca® (pirtobrutinib, 100 mg & 50 mg...
